Incyte’s MONJUVI Combo Approved by FDA for Relapsed/Refractory Follicular LymphomaIncyte has announced that the FDA has approved MONJUVI (tafasitamab-cxix) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). This makes it the first FDA-approved CD19- and CD20-targeted immunotherapy combination for this patient population. The approval is based on the pivotal Phase III inMIND trial, which showed a significant improvement in progression-free survival (PFS) with the MONJUVI regimen compared to the control arm. Patients receiving the combination therapy had a median PFS of 22.4 months...